Get the Stockscreener App
58.55
2.02%
1.16
After Hours:
58.55
Keros Therapeutics Inc stock is traded at $58.55, with a volume of 245.32K.
It is up +2.02% in the last 24 hours and down -3.64% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$57.39
Open:
$57.95
24h Volume:
245.32K
Relative Volume:
0.69
Market Cap:
$2.34B
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-12.90
EPS:
-4.54
Net Cash Flow:
$-146.15M
1W Performance:
+8.15%
1M Performance:
-3.64%
6M Performance:
+20.77%
1Y Performance:
+94.07%
1-Day Range:
$56.78
$58.81
1-Week Range:
$53.06
$58.81
52-Week Range:
$27.31
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
58.55 | 2.34B | 0 | -168.05M | -146.15M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewswire
Keros Therapeutics Showcases Innovations at Major Conferences - TipRanks
Keros Therapeutics CEO to Present at Major Healthcare Conferences in December | KROS Stock News - StockTitan
Keros Therapeutics’ (KROS) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $88.89 - Defense World
B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 16,103 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $88.89 Average Price Target from Analysts - MarketBeat
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Keros Therapeutics Reports Q3 2024 Financial Results - TipRanks
Long Term Trading Analysis for (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
What is Leerink Partnrs’ Estimate for KROS FY2024 Earnings? - Defense World
Equities Analysts Offer Predictions for KROS FY2024 Earnings - Defense World
William Blair Issues Pessimistic Forecast for KROS Earnings - MarketBeat
What is HC Wainwright's Estimate for KROS FY2024 Earnings? - MarketBeat
Wedbush Decreases Earnings Estimates for Keros Therapeutics - MarketBeat
Leerink Partnrs Has Negative Outlook of KROS FY2024 Earnings - MarketBeat
Wedbush Equities Analysts Cut Earnings Estimates for KROS - Defense World
FY2024 Earnings Estimate for KROS Issued By HC Wainwright - Defense World
Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group - Defense World
Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023) - Yahoo Finance
Brokers Offer Predictions for KROS Q3 Earnings - Defense World
Q3 Earnings Estimate for KROS Issued By Wedbush - MarketBeat
Interesting KROS Put And Call Options For April 2025 - Nasdaq
HC Wainwright Reaffirms Buy Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Brokers Set Expectations for KROS Q4 Earnings - Defense World
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire
KROSKeros Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Keros Therapeutics to Present at Guggenheim Conference - TipRanks
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - The Manila Times
Brokers Issue Forecasts for KROS Q4 Earnings - MarketBeat
Wedbush Upgrades Keros Therapeutics (NASDAQ:KROS) to Strong-Buy - MarketBeat
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire
Jefferies starts Keros Therapeutics with buy, $107 target By Investing.com - Investing.com Canada
(KROS) Proactive Strategies - Stock Traders Daily
Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Emerald Advisers LLC Acquires Shares of 155,545 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11 - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Analysts Offer Predictions for KROS FY2024 Earnings - Defense World
Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Cantor Fitzgerald Weighs in on KROS FY2024 Earnings - Defense World
Brokers Set Expectations for KROS FY2024 Earnings - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
(KROS) Trading Signals - Stock Traders Daily
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating - Investing.com India
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank - MarketBeat
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):